

**Louisiana Department of Health
Medicaid Pharmaceutical and Therapeutics Committee
628 North Fourth Street
Baton Rouge, LA
Bienville Building
Room #118
November 2, 2018
9:00 AM
DRAFT**

- I. Call to Order.....Marty McKay
- II. Parliamentary BusinessMarty McKay
 - A. Introduction of Members/Roll Call
 - B. Introduction of LDH & Magellan Staff
 - C. Announcement of Election of Officers – Chair and Co-Chair Elections
 - D. Approval of May 4, 2018 Meeting Minutes
 - E. Attendance/Additional Meetings
- III. P & T Committee OverviewMelwyn Wendt
 - A. P & T Background
 - B. P & T Bylaws
- IV. Ethics Review.....Haley Williams
- V. Single PDL.....Jen Steele
- VI. Reports.....Melwyn Wendt
 - A. Prior Authorization Monthly Report
 - B. PDL Reflecting May 4, 2018 P&T Committee Recommendations
- VII. New Business.....Doug Brown/Hind Douiki
 - A. Explanation of TOP\$, Monographs and Cost Sheets
 - B. Therapeutic Class Reviews of Drug Classes/Drug Manufacturer Testimony
 - 1. Alzheimer’s Agents
 - 2. Antidepressants, Other
 - 3. Antidepressants, SSRIs
 - 4. Antihistamines, Minimally Sedating
 - 5. Antihypertensives, Sympatholytics
 - 6. Antihyperuricemics
 - 7. Antiparkinson’s Agents
 - 8. Antipsoriatics, Oral
 - 9. Antipsoriatics, Topical
 - 10. Antipsychotics
 - 11. Anxiolytics

12. Bile Salts
13. Bronchodilators, Beta Agonist
14. Colony Stimulating Factors
15. COPD Agents
16. Cytokine and CAM Antagonists
17. Emollients
18. Epinephrine, Self-Injected
19. Erythropoiesis Stimulating Proteins
20. Glucocorticoids, Inhaled
21. Glucocorticoids, Oral
22. Hemophilia Treatment
23. Histamine II Receptor Blocker
24. Immunomodulators, Atopic Dermatitis
25. Immunomodulators, Topical
26. Intranasal Rhinitis Agents
27. Leukotriene Modifiers
28. Neuropathic Pain
29. NSAIDs
30. Oncology Oral – Breast
31. Oncology Oral – Hematologic
32. Oncology Oral - Lung
33. Oncology Oral – Other
34. Oncology Oral – Prostate
35. Oncology Oral – Renal Cell
36. Oncology Oral - Skin
37. Ophthalmic, Antibiotic-Steroid Combinations
38. Ophthalmic Antibiotics
39. Ophthalmics for Allergic Conjunctivitis
40. Ophthalmics, Anti-Inflammatories
41. Ophthalmics, Anti-Inflammatories/ Immunomodulator
42. Ophthalmics, Glaucoma Agents
43. Otic Anti-Infectives & Anesthetics
44. Otic Antibiotics
45. Progestational Agents
46. Sedative Hypnotics
47. Smoking Cessation
48. Steroids, Topical High
49. Steroids, Topical Low
50. Steroids, Topical Medium
51. Steroids, Topical Very High
52. Stimulants and Related Agents

VIII. New Single Drug Reviews.....Doug Brown/Hind Douiki

53. Analgesics, Narcotics Short – Roxybond®
54. Androgenic Agents – Androgel Gel Pump®
55. Androgenic Agents – Testosterone Gel Packet (AG Androgel®)

56. Androgenic Agents - Testosterone Gel Packet (Androgel®)
57. Androgenic Agents – Androgel Gel Packet®
58. Androgenic Agents - Testosterone Gel (AG Vogelxo®)
59. Androgenic Agents - Testosterone Gel (Vogelxo®)
60. Antibiotics, Inhaled – Kitabis Pak®
61. Antibiotics, Inhaled – Tobramycin Pak (AG)
62. Anticoagulants – Lovenox Vial®
63. Anticoagulants – Enoxaparin Sodium Vial (AG)
64. Antiemetic/Antivertigo Agents – Emend Capsule
65. Antiemetic/Antivertigo Agents – Aprepitant Capsule
66. Antiemetic/Antivertigo Agents - Akynzeo®
67. Antimigraine Agents, Triptans – Sumatriptan
68. Antimigraine Agents, Triptans – Imitrex®
69. Antiparasitics, Topical – Crotan®
70. Antivirals, Oral – Acyclovir Suspension
71. Antivirals, Oral – Tamiflu Suspension®
72. Antivirals, Oral – Oseltamivir Suspension
73. Antivirals, Oral – Zovirax Suspension®
74. Beta Blockers – Kapsargo®
75. Cephalosporins and Related Antibiotics - Daxbia®
76. Hypoglycemics, Insulin and Related Agents – Toujeo Solostar Pen®
77. Hypoglycemics, Insulin and Related Agents – Toujeo Max Solostar Pen®
78. Lipotropics, Statins – Zypitamag®
79. Platelet Aggregation Inhibitors – Aggrenox®
80. Platelet Aggregation Inhibitors – Aspirin/Dipyridamole
81. Platelet Aggregation Inhibitors – Aspirin/Dipyridamole (AG)
82. Proton Pump Inhibitors – Esomeprazole Kit

IX. Other Business

VIII. Next Steps

A. Proposed Therapeutic Classes to be Reviewed at Next Meeting

IX. Next Meeting Date – April 26, 2019 or May 3, 2019

X. Public Testimony